Literature DB >> 15957136

Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients.

Simon Desmeules1, Jean-François Arcand-Bossé, Jean Bergeron, Pierre Douville, Mohsen Agharazii.   

Abstract

BACKGROUND: Guidelines for the management of dyslipidemia in patients with chronic kidney disease are based on results from the fasting lipid profile, which can be difficult to obtain from patients on an afternoon or night dialysis schedule. The present study tests the hypothesis that nonfasting non-high-density lipoprotein (HDL) cholesterol (total cholesterol-HDL cholesterol) results are similar to fasting non-HDL results as a basis for the management of dyslipidemia in hemodialysis patients.
METHODS: Forty-eight long-term hemodialysis patients with a mean age of 63.6 years (42% with diabetes, 54% administered statins) participated in this study. For the lipid profile, blood samples were drawn after a 12-hour overnight fast (fasting) and again in a nonfasting state before the subsequent hemodialysis session. Data were analyzed by using paired t-test and regression analysis.
RESULTS: Non-HDL cholesterol values were nearly identical regardless of whether the patient was fasting (r2 = 0.995). Only 2 patients (4%) had a nonfasting triglyceride (TG) level greater than 500 mg/dL (> 5.6 mmol/L), which would have required confirmation after an overnight fast. Non-HDL values had the greatest level of correlation (absolute relative difference, 5.7%). When comparing the subgroup of patients with a TG level less than 200 mg/dL (< 2.3 mmol/L), nonfasting non-HDL cholesterol values identified 3 additional patients compared with fasting calculated low-density lipoprotein cholesterol for whom lipid-lowering therapy would have been introduced according to current guidelines.
CONCLUSION: In our study, non-HDL cholesterol levels were equivalent whether evaluated in the fasting or nonfasting state. We recommend that nonfasting non-HDL cholesterol level be used for the management of dyslipidemia in hemodialysis patients without imposing a 12-hour fast period.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15957136     DOI: 10.1053/j.ajkd.2005.03.002

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

1.  Serum non-high-density lipoprotein cholesterol (non-HDL-C) levels and cardiovascular mortality in chronic hemodialysis patients.

Authors:  Yoshihisa Echida; Tetsuya Ogawa; Kuniaki Otsuka; Yoshitaka Ando; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-02-29       Impact factor: 2.801

2.  Oxidized high-density lipoprotein is associated with protein-energy wasting in maintenance hemodialysis patients.

Authors:  Hirokazu Honda; Masashi Ueda; Shiho Kojima; Shinichi Mashiba; Hiroki Suzuki; Nozomu Hosaka; Yuki Hirai; Mari Nakamura; Hisako Nagai; Noriyuki Kato; Masanori Mukai; Makoto Watanabe; Keiko Takahashi; Kanji Shishido; Tadao Akizawa
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-15       Impact factor: 8.237

3.  The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics.

Authors:  Rosebud O Roberts; Yonas E Geda; David S Knopman; Ruth H Cha; V Shane Pankratz; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Ronald C Petersen; Walter A Rocca
Journal:  Neuroepidemiology       Date:  2008-02-07       Impact factor: 3.282

4.  Inverse Association Between Serum Non-High-Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis.

Authors:  Tae Ik Chang; Elani Streja; Gang Jee Ko; Neda Naderi; Connie M Rhee; Csaba P Kovesdy; Moti L Kashyap; Nosratola D Vaziri; Kamyar Kalantar-Zadeh; Hamid Moradi
Journal:  J Am Heart Assoc       Date:  2018-06-09       Impact factor: 5.501

5.  Drinking Water-Associated PFAS and Fluoroethers and Lipid Outcomes in the GenX Exposure Study.

Authors:  Emma M Rosen; Nadine Kotlarz; Detlef R U Knappe; C Suzanne Lea; David N Collier; David B Richardson; Jane A Hoppin
Journal:  Environ Health Perspect       Date:  2022-09-07       Impact factor: 11.035

6.  Utility of non-HDL-C in predicting proteinuria remission of idiopathic membranous nephropathy: a retrospective cohort study.

Authors:  Lei Dong; Wang Wei; Min Han; Gang Xu
Journal:  Lipids Health Dis       Date:  2021-09-29       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.